Database : HANSEN Search on : TESTES DE SENSIBILIDADE MICROBIANA/METODOS [Subject descriptor] References found : 19 [refine] Displaying: 1 .. 19   in format [Detailed]

page 1 de 1

1 / 19

HANSEN

select to print

Id: 18390 Author: Ebenezer, G. J; Norman, G; Joseph, G. A; Daniel, S; Job, C. K Title: Drug resistant-Mycobacterium leprae- results of mouse footpad studies from a laboratory in South India ..- Source: s.l; s.n; 2002. 12 p. tab. Abstract: Out of 265 biopsies of leprosy patients received at the Experimental Laboratory of Schieffelin Leprosy Research and Training Centre from 1987 to 1997 for evaluating resistant strains of M. leprae using the mouse footpad technique, 49 showed resistant strains of M. leprae to varying concentration of dapsone, rifampicin and clofazimine. 23 (47%) of these were from a control area. With 369 skin-smear positive multibacillary (MB) patients as the risk group (denominator), 23 (6.23%) were resistant to one or more drugs. 18 (4.88%) had dapsone resistance, 5 (1.36%) were resistant to rifampicin and 9 (2.44%) had resistance to low concentrations of clofazimine (0.0001%). Out of the 23 biopsies with drug resistance from the control area, primary dapsone resistance was seen in 7 (30%) biopsies and secondary dapsone resistance in 11 (48%). Primary rifampicin resitance was seen in 4 (17.4%) patients, secondary rifampicin resistance in 1 (4.35%) and primary clofazimine resistance in 7 (30%). 3 (13%) of the strains showed secondary clofazimine resistance. One biopsy had resistent strains to all the three drugs. In a control area where properly supervised effective multidrug therapy (MDT) was regularly administered over the years, the emergence of drug resistance is negligible. It may not be the case if the content, duration and regularity of the drug regimen were not satisfactory. Aware of the possible shortcomings in mass administration of MDT, it is emplasized that mouse footpad studies on drug resistance should be made available at least in endemic areas where the incidence of the disease has not changed despite good MDT coverage in order to monitor the emergence of drug resistance. Research into molecular biological identification of drug resistant-M.leprae should be intensified. These steps would help to institute timely measures to check the spread of any drug-resistant organisms in the community (AU). Descriptors: MYCOBACTERIUM LEPRAE/cresc MYCOBACTERIUM LEPRAE/isol MYCOBACTERIUM LEPRAE/metab MYCOBACTERIUM LEPRAE/patogen MYCOBACTERIUM LEPRAE/ultraest RESISTÊNCIA A DROGAS DAPSONA/uso terap CLOFAZIMINA/uso terap RIFAMPINA/uso terap TESTES DE SENSIBILIDADE MICROBIANA/métodos TESTES DE SENSIBILIDADE MICROBIANA/vet - HANSENIASE/clas  HANSENIASE/compl  HANSENIASE/quimioter  HANSENIASE/imunol  HANSENIASE/microbiol  HANSENIASE/patol  OFLOXACINO/uso terap  MINOCICLINA/uso terap Limits: HUMANO Location: BR191.1; 09299/s

2 / 19

HANSEN

select to print

Id: 18385 Author: Consigny, Sophie; Bentoucha, Abdelhalim; Bonnafous, Pascale; Grosset, Jacques; Ji, Baohong Title: Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice ..- Source: s.l; s.n; 2000. 3 p. tab. Abstract: Bactericidal activities of HMR 3647 (HMR), moxifloxacin (MXFX), and rifapentine (RPT) against Mycobacterium leprae, measured by the proportional bactericidal technique in the mouse footpad system, were compared with those of the established antileprosy drugs clarithromycin (CLARI), ofloxacin (OFLO), and rifampin (RMP. Administered in five daily doses of 100 mg/kg of body weight, HMR appeared slightly more bactericidal than CLARI. In a single dose, MXFX at 150 mg/kg was more active than the same dose of OFLO and displayed exactly the same level of activity as RMP at 10 mg/kg; the combination MXFX-minocycline (MINO) (MM) was more bactericidal than the combination OFLO-MINO (OM); RPT at 10mg/kg was more bactericidal than the same dose of RMP and even more active than the combination RMP-OFLO-MINO (ROM); the combination RPT-MXFX-MINO (PMM) killed 99.9% of viable M. leprae and was slighthy more bactericidal than RPT alone, indicating that the combination PMM showed an additive effect against M. leprae (AU). Descriptors: HANSENIASE/quimioter HANSENOSTATICOS/admin HANSENOSTATICOS/farmacol HANSENOSTATICOS/farmacocin HANSENOSTATICOS/uso terap MYCOBACTERIUM LEPRAE TESTES DE SENSIBILIDADE MICROBIANA/métodos DROGAS EM INVESTIGACAO/admin DROGAS EM INVESTIGACAO/anal DROGAS EM INVESTIGACAO/uso terap - BACTERICIDAS  QUIMIOTERAPIA COMBINADA  MYCOBACTERIUM LEPRAE/metab  MYCOBACTERIUM LEPRAE/fisiol  DAPSONA/uso terap  RIFAMPINA/uso terap  CLOFAZIMINA/uso terap  OFLOXACINO/uso terap  MINOCICLINA/uso terap  CLARITROMICINA/uso terap Limits: ESTUDO COMPARATIVO Location: BR191.1; 09311/s

3 / 19

HANSEN

select to print

Id: 18225 Author: Ebenezer, G. J; Norman, G; Joseph, G. A; Daniel, S; Job, C. K Title: Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India ..- Source: s.l; s.n; 2002. 12 p. tab. Abstract: Out of 265 biopsies of leprosy patients received at the Experimental Pathology Laboratory of Schieffelin Leprosy Research and Training Centre from 1987 to 1997 for evaluating resistant strains of M. leprae, using the mouse footpad technique, 49 showed resistant strains of M leprae to varying concentrations of dapsone, rifampicin and clofazimine. 23 (47%) of these were from a control area. With 369 skin-smear positive multibacillary (MB) patients as the risk group (denominator), 23 (6.23%) were resistant to one or more drugs. 18 (4.88%) had dapsone resistance, 5 (1.36%) were resistant to rifampicin and 9 (2.44%) had resistance to low concentrations of clofazimine (0.0001%). Out of the 23 biopsies with drug resistance from the control area, primary dapsone resistance was seen in 7 (30%) biopsies and secondary dapsone resistance in 11 (48%). Primary rifampicin resistance was seen in 4 (17.4%) patients, secondary rifampicin resistance in 1 (4.35%) and primary clofazimine resistance in 7 (30%). 3 (13%) of the strains showed secondary clofazimine resistance. One biopsy had resistant strains to all the three drugs. In a control area where properly supervised effective multidrug therapy (MDT) was regularly administered over the years, the emergence of drug resistance is negligible. It may not be the case if the content, duration and regularity of the drug regimen were not satisfactory. Aware of the possible shortcomings in mass administration of MDT, it is emphasized that mouse footpad studies on drug resistance should be made available at least in endemic areas where the incidence of the disease has not changed despite good MDT coverage in order to monitor the emergence of drug resistance. Research into molecular biological identification of drug resistant-M.leprae should be intensified. These steps would help to institute timely measures to check the spread of any drug-resistant organisms in the community. (AU). Descriptors: Clofazimina/PD Dapsona/PD Farmacorresistência Bacteriana Farmacorresistência Bacteriana Múltipla Índia Hansenostáticos/*PD Hanseníase/*DT/MI Camundongos Camundongos Endogâmicos CBA Testes de Sensibilidade Microbiana Mycobacterium leprae/*DE Rifampina/PD Limits: HUMANO ANIMAL MASCULINO FEMININO Location: BR191.1; 09179/S

4 / 19

HANSEN

select to print

Id: 15629 Author: Salem, Isam Ismail; Steffan, Gerhard; Düzgünes, Nejat Title: Efficacy of clofazimine - modified cyclodextrin against Mycobacterium avium complex in human macrophages ..- Source: s.l; s.n; 2003. 10 p. graf. Abstract: Clofazimine, a water insoluble substituted iminophenazine derivative with anti-mycobacterial and anti-inflammatory activity, is recommended by the WHO for the treatment of leprosy. It is also active against disseminated Mycobacterium avium complex (MAC) disease in HIV-infected patients. Recently, we achieved a 4000-fold increase of clofazimine water solubility using a novel modified clofazimine-cyclodextrin complex synthesized and patented by our group [Wasserlösliche, Iminiophenazinderivate enthaltende pharmazeutische Zusammensetzungen, deren Herstellung und Verwendung, German Patent, DE19814814C2]. In this paper we examine the activity of this complex against MAC in human macrophages, and evaluate its cytotoxicity. MAC-infected macrophages were treated for 24h with free or complexed clofazimine. The in vitro minimum inhibitory concentrations of both free and complexed clofazimine were 0.1 microg/ml. Free and complexed clofazimine inhibited the growth of MAC inside macrophages to a similar extent, while modified cyclodextrin alone had no observable effects on MAC or macrophages. Complexed clofazimine was not toxic to cells at concentrations effective against MAC. The TD(50) of the modified cyclodextrin in THP-1 cell line was 297 microg/ml. (AU). Descriptors: ANTIINFECCIOSOS/quim ANTIINFECCIOSOS/farmacol ANTIINFECCIOSOS/tox CELULAS CULTIVADAS CLOFAZIMINA/quim CLOFAZIMINA/farmacol CLOFAZIMINA/tox MACROFAGOS/ef drogas TESTES DE SENSIBILIDADE MICROBIANA COMPLEXO MYCOBACTERIUM AVIUM/ef drogas ESTEROIS/quim ACIDO SUCCINICO Limits: ESTUDO COMPARATIVO HUMANO ANIMAL CAMUNDONGOS Electronic Medium: http://www.ilsl.br Location: BR191.1; 09082/s

5 / 19

HANSEN

select to print

Id: 13945 Author: Salem, Isam Ismail; Steffan, Gerhard; Düzgünes, Nejat Title: Efficacy of clofazimine - modified cyclodextrin against Mycobacterium avium complex in human macrophages ..- Source: s.l; s.n; 2003. 10 p. graf. Abstract: Clofazimine, a water insoluble substituted iminophenazine derivative with anti-mycobacterial and anti-inflammatory activity, is recommended by the WHO for the treatment of leprosy. It is also active against disseminated Mycobacterium avium complex (MAC) disease in HIV-infected patients. Recently, we achieved a 4000-fold increase of clofazimine water solubility using a novel modified clofazimine-cyclodextrin complex synthesized and patented by our group [Wasserlösliche, Iminiophenazinderivate enthaltende pharmazeutische Zusammensetzungen, deren Herstellung und Verwendung, German Patent, DE19814814C2]. In this paper we examine the activity of this complex against MAC in human macrophages, and evaluate its cytotoxicity. MAC-infected macrophages were treated for 24h with free or complexed clofazimine. The in vitro minimum inhibitory concentrations of both free and complexed clofazimine were 0.1 microg/ml. Free and complexed clofazimine inhibited the growth of MAC inside macrophages to a similar extent, while modified cyclodextrin alone had no observable effects on MAC or macrophages. Complexed clofazimine was not toxic to cells at concentrations effective against MAC. The TD(50) of the modified cyclodextrin in THP-1 cell line was 297 microg/ml. (AU). Descriptors: ANTIINFECCIOSOS/quim ANTIINFECCIOSOS/farmacol ANTIINFECCIOSOS/tox CLOFAZIMINA/quim CLOFAZIMINA/farmacol CLOFAZIMINA/tox CELULAS CULTIVADAS MACROFAGOS/ef drogas MACROFAGOS/microbiol TESTES DE SENSIBILIDADE MICROBIANA COMPLEXO MYCOBACTERIUM AVIUM/ef drogas ESTEROIS/quim ACIDO SUCCINICO/quim Limits: ESTUDO COMPARATIVO HUMANO ANIMAL CAMUNDONGOS Electronic Medium: http://www.ilsl.br Location: BR191.1; 09082/s

6 / 19

HANSEN

select to print

Id: 13618 Author: Reichart, P. A; Samaranayake, L. P; Samaranayake, Y. H; Grote, M; Pow, E; Cheung, B Title: High oral prevalence of Candida krusei in leprosy patients in northern Thailand ..- Source: s.l; s.n; Dec.2002. 7 p. tab, graf. Abstract: Although Candida albicans is the most common human yeast pathogen, other Candida species such as C. krusei are now recognized as emerging agents, especially in patients with human immunodeficiency virus (HIV) disease. C. krusei is inherently resistant to the widely used triazole antifungal fluconazole and poses therapeutic problems, especially in systemic candidiasis. In a surveillance study of leprosy patients (with arrested or burnt-out disease) in a leprosarium in northern Thailand, we found a rate of oral carriage of C. krusei (36 per cent) significantly (P smaller 0.05) higher than that for a healthy control group (10 per cent). Among the Candida-positive patients, 16 of 35 (46 per cent) carried C. krusei, while C. albicans was the second most common isolate (12 of 35 patients; 34 per cent). The corresponding figures for the control group were 2 of 13 (15 per cent) and 6 of 13 (46 per cent), respectively. Studies of the antifungal resistance of the C. krusei isolates from patients indicated that all except one of the isolates were resistant to fluconazole, two isolates were resistant to ketoconazole, and all isolates were sensitive to amphotericin B. Evaluation of their genetic profiles by randomly amplified polymorphic DNA analysis with three different primers and subsequent analysis of the gel profiles by computerized cluster-derived dendrograms revealed that the C. krusei isolates from patients belonged to 10 disparate clusters, despite the origin from a single locale. These nascent findings indicate an alarmingly high prevalence of a Candida species resistant to a widely used antifungal in a part of the world where HIV disease is endemic. (AU). Descriptors: ANTIMICOTICOS/farmacol CANDIDA/clas CANDIDA/ef drogas CANDIDA/genet CANDIDA/isol CANDIDIASE BUCAL/compl CANDIDIASE BUCAL/epidemiol CANDIDIASE BUCAL/microbiol PORTADOR/epidemiol PORTADOR/microbiol Resistência Fúngica a Múltiplas Drogas HANSENIASE/compl TESTES DE SENSIBILIDADE MICROBIANA BOCA/microbiol PREVALÊNCIA TECNICA DE AMPLIFICACAO AO ACASO DE DNA POLIMORFICO TAILÂNDIA/epidemiol Limits: HUMANO MASCULINO FEMININO MEIA-IDADE IDOSO IDOSO DE 80 ANOS OU MAIS Location: BR191.1; 09003/s

7 / 19

HANSEN

select to print

Id: 13262 Author: Goodwin, C. S; Wood, M. J Title: Bacteria isolated from plantar ulcers of Ethiopian leprosy patients, with the antibacterial drug sensitivities of the isolates ..- Source: s.l; s.n; 1970. 6 p. tab. Abstract: Bacteriological sampling of grossly infected or chronic plantar ulcers was perfomed in 39 untreated patients with leprosy and in 22 patients who had received antibiotic treatment. Samples were cultured aerobically and anaerobically, and films of pus were stained by Gram´s method. Stained films gave little indication of the type of infecting pathogen, except when Gram-positive cocci alone were seen. From the ulcers of patients untreated with antibiotics anaerobic streptococci were isolated more frequently than any other organism, and and this may be an original observation. Of the 8 Staphylococcus aureus isolates 5 were penicillin sensitive. A renge of Gram-negative bacteria, but no Clostridia, were isolated. From the ulcers of patients who had received antibiotics penicillin-resistant Staph. aureus was most frequently isolated. Some Gram-positive bacteria resistant to tetracycline were sensitive to doxycycline.(AU). Descriptors: ANTIBIOTICOS/uso terap BACTERIAS/isol DERMATOSES DO PE/quimioter HANSENIASE/compl TESTES DE SENSIBILIDADE MICROBIANA PENICILINAS/uso terap ULCERA CUTÂNEA/quimioter ULCERA CUTÂNEA/microbiol STAPHYLOCOCCUS/isol STREPTOCOCCUS/isol Limits: HUMANO MASCULINO FEMININO ADULTO MEIA-IDADE ADOLESCENTE Electronic Medium: http://www.ilsl.br Location: BR191.1; 00740/s

8 / 19

HANSEN

select to print

Id: 13258 Author: Heifets, Leonid B Title: Synergistic effect of rifampin, streptomycin, ethionamide, and ethambutol on Mycobacterium intracellulare ..- Source: s.l; s.n; jan. 1982. 6 p. tab, graf. Abstract: A method of quantitative estimation to determine the interaction of antituberculosis drugs is suggested. The design of experiments, performed on 7H11 agar plates, is adjusted to the following statistical treatment by combined use of probit analysis and isobologram methods. By plotting the values reflecting the inhibition of 75% of the bacterial population (ED75) with their confidence limits on the isobologram, it was found that the clearest results proving synergism between the drugs could be obtained. Six 2-drug combinations and 6 3-drug combinations were tested against strains of Mycobacterium intracellulare (serovar 8), and a synergistic effect was demonstrated in most of them. These were various combinations of rifampin, streptomycin, ethambutol, and ethionamide. The application of probit analysis to the data derived from testing single drugs can provide a quantitative estimation of the actual drug resistance of the M. intracellulare strains.(AU). Descriptors: SINERGISMO DE DROGAS TESTES DE SENSIBILIDADE MICROBIANA MICOBACTERIAS ATIPICAS/ef drogas MYCOBACTERIUM/ef drogas ETAMBUTOL/farmacol ETIONAMIDA/farmacol RIFAMPINA/farmacol ESTREPTOMICINA/farmacol Limits: SUPPORT, NON-U.S. GOV'T Electronic Medium: http://www.ilsl.br Location: BR191.1; 00960/s

9 / 19

HANSEN

select to print

Id: 13234 Author: Chatterjee, B. D; Chakraborti, C. K; Chaudhuri, S Title: Microflora in the trophic ulcers of the foot in leprosy ..- Source: s.l; s.n; oct. 1985. 4 p. tab. Abstract: Out of 25 cases of trophic ulcers of the foot, 10 (40%) were both aerobic and anaerobic, 14 (56%) only aerobic and one (4%) showed no growth of bacteria. With the exception of two cases (8%) in the aerobic group, all others showed mixed infections. A wide range of bacteria is reported. Topical application of gentamicin and chloramphenicol is recommended, based on the results of in vitro sensitivity.(AU). Descriptors: DOENCAS DO PE/microbiol HANSENIASE/microbiol TESTES DE SENSIBILIDADE MICROBIANA ULCERA CUTÂNEA/microbiol BACTERIAS ANAEROBIAS/ef drogas BACTERIAS ANAEROBIAS/isol BACTERIAS AEROBIAS/ef drogas BACTERIAS AEROBIAS/isol Limits: HUMANO Electronic Medium: http://www.ilsl.br Location: BR191.1; 02156/s

10 / 19

HANSEN

select to print

Id: 11750 Author: Cambau, Emmanuelle; Bonnafous, Pascale; Perani, Evelyne; Sougkoff, Wladimir; Ji, Baohong; Jarlier, Vicent Title: Molecular detection of rifampin and ofloxacin resistance for patients Who experience relapse of multibacillary leprosy ..- Source: s.l; s.n; 2002. 7 p. tab. Descriptors: DNA BACTERIANO MYCOBACTERIUM LEPRAE MYCOBACTERIUM LEPRAE OFLOXACINA RECIDIVA RIFAMPINA ANTIBIOTICOS ANTITUBERCULOSE DNA TOPOISOMERASE (ATP-HIDROLISANTE) DNA TOPOISOMERASE (ATP-HIDROLISANTE) MODELOS ANIMAIS DE DOENÇAS TESTES DE SENSIBILIDADE MICROBIANA HANSENIASE MUTAÇAO PROTEINAS DE PLANTAS PROTEINAS DE PLANTAS Location: BR191.1; 08526/s; BR191.1; 08659/s

11 / 19

HANSEN

select to print

Id: 11469 Author: darricarrere T, Rafael; Ojeda Sch, Alicia Title: Aioslamiento de corynebacterium grupo "JK" (CJK) en pacientes inmunocomprometidos ?- Source: s.l; s.n; 1987. 6 p. tab. Descriptors: CORYNEBACTERIUM HOSPEDEIRO IMUNOCOMPROMETIDO LUPUS ERITEMATOSO SISTEMICO HANSENIASE TUBERCULOIDE LEISHMANIOSE MUCOCUTANEA TESTES DE SENSIBILIDADE MICROBIANA RETO Location: BR191.1; 08347/s

12 / 19

HANSEN

select to print

Id: 11445 Author: Consigny, Sophie; Bentoucha, Abdelhalim; Bonnafous, Pascale; Grosset, Jacques; Ji, Baohong Title: Bactericidal activities of HMR 3647, monofloxacin, and rifapentine against mycobacterium leprae in mice ..- Source: s.l; s.n; 2000. 3 p. tab. Descriptors: AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA AGENTES ANTIINFECCIOSOS DE FLUOROQUINOLONA ANTIBIOTICOS MACROLIDIOS ANTIBIOTICOS MACROLIDIOS PÉ LEPROSTATICOS LEPROSTATICOS HANSENIASE HANSENIASE CAMUNDONGOS TESTES DE SENSIBILIDADE MICROBIANA MYCOBACTERIUM LEPRAE RIFAMPINA RIFAMPINA RIFAMPINA Limits: ESTUDO COMPARATIVO ANIMAL Location: BR191.1; 08327/s

13 / 19

HANSEN

select to print

Id: 10148 Author: Dhople, Arvind M; Williams, Sharon L Title: The activity of rifabutin against Mycobacterium leprae in armadillos ..- Source: s.l; s.n; 1997. 5 p. tab. Descriptors: TATUS MODELOS ANIMAIS DE DOENÇAS LEPROSTATICOS LEPROSTATICOS LEPROSTATICOS HANSENIASE HANSENIASE CAMUNDONGOS CAMUNDONGOS ENDOGAMICOS BALB C TESTES DE SENSIBILIDADE MICROBIANA MYCOBACTERIUM LEPRAE MYCOBACTERIUM LEPRAE RIFABUTINA RIFABUTINA RIFABUTINA Limits: ANIMAL Location: BR191.1; 07112/s

14 / 19

HANSEN

select to print

Id: 9907 Author: Franzblau, Scott G; Chan, Gertrude P; Garcia-Ignacio, Bernadette G; Chavez, Virginia E; Livelo, Jocelyn B; Jimenez, Claribel L; Parrilla, Manuela Luiza R; Calvo, Rally F; Williams, Diana L; Gillis, Thomas P Title: Clinical trial of fusidic acid for lepromatous leprosy ..- Source: s.l; s.n; 1994. 4 p. tab. Descriptors: ADOLESCENCIA CRIANÇA PÉ PÉ ACIDO FUSIDICO GLICOLIPIDIOS HANSENIASE LEPROMATOSA HANSENIASE LEPROMATOSA CAMUNDONGOS TESTES DE SENSIBILIDADE MICROBIANA MYCOBACTERIUM LEPRAE MYCOBACTERIUM LEPRAE REAÇAO EM CADEIA POR POLIMERASE PELE ESPIROMETRIA FATORES DE TEMPO Limits: ANIMAL Location: BR191.1; 06884/s

15 / 19

HANSEN

select to print

Id: 9634 Author: Jamil, S; Keer, J. T; Lucas, S. B; Dockrell, H. M; Chiang, T. J; Hussain, R; Stoker, N. G Title: Use of polymerase chain reaction to assess efficacy of leprosy chemotherapy ..- Source: s.l; s.n; 1993. 5 p. tab. Descriptors: SEQUENCIA DE BASES DNA BACTERIANO LEPROSTATICOS LEPROSTATICOS HANSENIASE HANSENIASE TESTES DE SENSIBILIDADE MICROBIANA DADOS DE SEQUENCIA MOLECULAR MYCOBACTERIUM LEPRAE MYCOBACTERIUM LEPRAE REAÇAO EM CADEIA POR POLIMERASE Location: BR191.1; 06558/s

16 / 19

HANSEN

select to print

Id: 9539 Author: Tomioka, H; Sato, K; Saito, H Title: Comparative in vitro and in vivo activity of fleroxacin and ofloxacin against various mycobacteria ..- Source: s.l; s.n; 1991. 5 p. tab. Descriptors: MODELOS ANIMAIS DE DOENÇAS FLEROXACINA FLEROXACINA HANSENIASE CAMUNDONGOS CAMUNDONGOS ENDOGAMICOS BALB C TESTES DE SENSIBILIDADE MICROBIANA MYCOBACTERIUM MICOBACTERIOSE ATIPICA MYCOBACTERIUM AVIUM MYCOBACTERIUM TUBERCULOSIS OFLOXACINA OFLOXACINA Location: BR191.1; 06265/s

17 / 19

HANSEN

select to print

Id: 9128 Author: Mocellin, Marcos; Repka, Joao; Stahlke, Luciana Gabardo; Catani, Guilherme S; Stahlke, Paulo S. D. B; Yosida, Luiz; Cabrera, Pablo F. A Title: Avaliacao da microbiota bacteriana nasal de hansenianos Evaluation of the nasal bacterial microbiota of bearers of Hansen's disease- Source: s.l; s.n; 1998. 6 p. ilus, tab. Descriptors: MUCOSA NASAL RESISTENCIA MICROBIANA A DROGAS HANSENIASE RIFAMPINA CLOFAZIMINA DAPSONA ANTIBIOTICOS COMBINADOS TESTES DE SENSIBILIDADE MICROBIANA GRUPOS CONTROLE PROTEUS MIRABILIS ESCHERICHIA COLI PSEUDOMONAS AERUGINOSA OXACILINA Location: BR191.1; 06086/s

18 / 19

HANSEN

select to print

Id: 8369 Author: Franzblau, Scott G; Hastings, Robert C Title: Rapid in vitro metabolic screen for antileprosy compounds ..- Source: s.l; s.n; 1987. 4 p. tab, graf. Descriptors: HANSENIASE MYCOBACTERIUM LEPRAE MYCOBACTERIUM LEPRAE ADENOSINA TRIFOSFATO LEPROSTATICOS TESTES DE SENSIBILIDADE MICROBIANA Location: BR191.1; 02414/s

19 / 19

HANSEN

select to print

Id: 3809 Author: David, Hugo L; Clavel, Sabine; Clement, Françoise; Moniz-Pereira, José Title: Effects of antituberculosis and antileprosy drugs on mycobacteriophage D29 growth ..- Source: s.l; s.n; 1980. 2 p. graf, tab. Descriptors: MYCOBACTERIUM ANTITUBERCULOSOS ANTIVIRAIS LEPROSTATICOS TESTES DE SENSIBILIDADE MICROBIANA MICOBACTERIOFAGOS MICOBACTERIOFAGOS Location: BR191.1; 02649/s

---

page 1 de 1

Refine the search

Database : HANSEN

Advanced form

Search for : Free form

		Search	in field
1			WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
2	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
3	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type

Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO Latin American and Caribbean Center on Health Sciences Information